Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Favier, B.
Right arrow Articles by Latour, J. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Favier, B.
Right arrow Articles by Latour, J. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 9, No. 1, 15-20 (2003)
DOI: 10.1191/1078155203jp102oa
© 2003 SAGE Publications

External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers

Bertrand Favier, PharmD

Pharmacy Department, Centre Régional de Lutte Contre le Cancer Léon Bérard, 28 rue Laënnec, 69008 Lyon, France

Laurence Gilles, PharmD

Pharmacy Department, Centre Régional de Lutte Contre le Cancer Léon Bérard, 28 rue Laënnec, 69008 Lyon, France

Claude Ardiet, PharmD

Pharmacy Department, Centre Régional de Lutte Contre le Cancer Léon Bérard, 28 rue Laënnec, 69008 Lyon, France

Jean François Latour, PharmD

Pharmacy Department, Centre Régional de Lutte Contre le Cancer Léon Bérard, 28 rue Laënnec, 69008 Lyon, France

Objectives. The aim of this report was to study the external contamination of vials of 5-fluorour-acil, cyclophosphamide, ifosfamide, etoposide, doxorubicin and docetaxel. It also investigated the possible contamination of 5-fluorouracil outer packaging.

Methods. External contamination was measured on vials containing 5-fluorouracil, etoposide, cyclophosphamide, ifosfamide, doxorubicin and docetaxel. Samples from the outer wall of the vials were obtained by immersing and rotating the stoppered vials for 30 seconds in water for injections.

Results. All vials tested were contaminated with quantities varying from 0.5 ng to 2.4 g per vial, depending on the supplier. The outer packaging containing 25 vials of 5-fluorouracil was contaminated with 1.5 g, but no contamination was detected on the plastic packaging of etoposide.

Conclusion. These results demonstrate that the environment of operators may be contaminated, even in the absence of any handling error, and that contamination is present even before the cytotoxic reconstitution has begun. This source of exposure to cytotoxics may account for the contamination detected in the urine of operators. We demonstrate the necessity of protecting effectively all skin surfaces that are likely to come into contact with antineoplastic agents when unpacking the vials. Wearing long disposable gloves with adequate thickness (such as surgical gloves) is strongly recommended, from the very moment operators enter the preparation room. In general, the contamination of operators can only be controlled efficiently when all possible sources of contamination are considered, and suitable protection facilities are used (safety cabinet or isolator).

Key Words: contamination • cytotoxic agent • environment • exposure • vial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J Oncol Pharm PractHome page
Section 1 Introduction
Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 3 - 6.
[PDF]


Home page
J Oncol Pharm PractHome page
Section 10 Chemical contamination monitoring
Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 44 - 48.
[PDF]


Home page
CA Cancer J ClinHome page
T. H. Connor and M. A. McDiarmid
Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings
CA Cancer J Clin, November 1, 2006; 56(6): 354 - 365.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
T. H CONNOR
Hazardous anticancer drugs in health care: environmental exposure assessment.
Ann. N.Y. Acad. Sci., September 1, 2006; 1076: 615 - 623.
[Abstract] [Full Text] [PDF]


Home page
ANN OCCUP HYGHome page
S. CRAUSTE-MANCIET, P. J. M. SESSINK, S. FERRARI, J.-Y. JOMIER, and D. BROSSARD
Environmental Contamination with Cytotoxic Drugs in Healthcare Using Positive Air Pressure Isolators
Ann. Hyg., October 1, 2005; 49(7): 619 - 628.
[Abstract] [Full Text] [PDF]


Home page
ANN OCCUP HYGHome page
M. HEDMER, A. GEORGIADI, E. R. BREMBERG, B. A. G. JONSSON, and S. EKSBORG
Surface Contamination of Cyclophosphamide Packaging and Surface Contamination with Antineoplastic Drugs in a Hospital Pharmacy in Sweden
Ann. Hyg., October 1, 2005; 49(7): 629 - 637.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
T. H. Connor, P. J. M. Sessink, B. R. Harrison, J. R. Pretty, B. G. Peters, R. M. Alfaro, A. Bilos, G. Beckmann, M. R. Bing, L. M. Anderson, et al.
Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies
Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 475 - 484.
[Abstract] [Full Text] [PDF]